Kovaltry

Octocog alfa, the active ingredient in Kovaltry, is a recombinant factor VIII presented as a solution for injection for intravenous use. It treats hemophilia A, including congenital factor VIII deficiency and acquired hemophilia A, by replacing missing clotting factor.

GNH USA supplies Kovaltry as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kovaltry is used to manage bleeding disorders that involve the intrinsic coagulation pathway, particularly hemophilia A.

- Hemophilia A (congenital factor VIII deficiency): provides factor VIII replacement to prevent or control bleeding episodes. - Acquired hemophilia A: supplies recombinant factor VIII to restore clotting function in patients with autoantibody‑mediated deficiency. - Perioperative management of bleeding in patients with hemophilia A: ensures adequate hemostasis during surgery or invasive procedures.

Kovaltry may cause a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema - Headache - Fever - Arthralgia - Nausea - Fatigue

Serious or Rare Side Effects: - Development of neutralizing antibodies (inhibitors) against factor VIII - Anaphylaxis or severe allergic reaction - Thromboembolic events - Disseminated intravascular coagulation - Severe hemolysis - Acute systemic hypersensitivity

Before using Kovaltry, consider the following precautions.

- Bleeding risk assessment: evaluate baseline factor VIII levels prior to therapy. - Inhibitor monitoring: test periodically for anti‑factor VIII antibodies. - Surgical planning: coordinate dosing with the surgical team to maintain hemostasis. - Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited. - Renal/hepatic impairment: monitor clinical response and adjust as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kovaltry can interact with other medicines; review the following.

Major Interactions (Avoid): - Concurrent use of other factor VIII products: may cause additive clotting effect. - Immune tolerance induction agents: may increase risk of inhibitor development. - High‑dose antifibrinolytics (e.g., tranexamic acid): may elevate thrombosis risk.

Moderate Interactions (Monitor Closely): - Activated prothrombin complex concentrates: monitor for thrombotic complications. - Live vaccines: observe for altered immune response. - Certain antibiotics (e.g., aminoglycosides): may affect infusion site tolerance.